Clinical trial · Interventional
Pancreatic Ductal Adenocarcinoma - Microbiome as Predictor of Subtypes
NCT04922515CI-TRIAL-00052205PDA-MAPSunknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The prospective clinical trial "PDA-MAPS - Pancreatic ductal adenocarcinoma - Microbiome as Predictor of Subtypes" aims to investigate the prognostic and predictive power of the orointestinal and tumoral microbiome in PDAC patients and associate findings with genetic, transcriptional and clinical data, in particular with treatment response.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Oral and rectal swabs for microbiome sequencing | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Progression free survival
- timeFrame
- 12 months upon study enrollment
- description
- Progression free survival of patients measured in months
Secondary outcomes (2)
- measure
- Molecular subtypes of pancreatic cancer
- timeFrame
- within 3 months of histological diagnosis
- description
- Basal and classical subtype via RNAseq from tissue samples
- measure
- Response to chemotherapy
- timeFrame
- up to 6 months after start of therapy
- description
- reponse, partial response and progress according to RECIST within 6 months of therapy initiation
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria: \- Patients with pancreatic mass suspicious of pancreatic ductal adenocarcinoma Exclusion Criteria: * \< 18 years * patients that cannot give informed consent * pregnant and breastfeeding women
References
Publications (0)
Data not yet available
No reference posted for this study.